Correspondence 0001104659-23-059144 from Addex Therapeutics Ltd. (ADXN) (CIK 0001574232) (ADXN)
Addex Therapeutics Ltd. (ADXN) (CIK 0001574232)
Date: May 11, 2023 · CIK: 0001574232 · Accession: 0001104659-23-059144
AI Filing Summary & Sentiment
File numbers found in text: 333-271611
Letter
Addex Therapeutics Ltd
Chemin des Mines 9,
CH-1202 Geneva, Switzerland
May 11, 2023 Via Edgar
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Alan Campbell
RE: Addex Therapeutics Ltd
Registration Statement on Form F-1
File No. 333-271611
Acceleration Request
Requested Date: May 12,
Requested Time: 4:00 P.M. Eastern Time
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-271611) (the “Registration Statement”) to become effective on May 12, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Josh Kaufman, counsel to the Registrant, at (212) 479-6495.
Very truly yours,
Addex Therapeutics Ltd.
Show Raw Text
CORRESP 1 filename1.htm Addex Therapeutics Ltd Chemin des Mines 9, CH-1202 Geneva, Switzerland May 11, 2023 Via Edgar United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Alan Campbell RE: Addex Therapeutics Ltd Registration Statement on Form F-1 File No. 333-271611 Acceleration Request Requested Date: May 12, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form F-1 (File No. 333-271611) (the “Registration Statement”) to become effective on May 12, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. Once the Registration Statement has been declared effective, please orally confirm that event with Josh Kaufman, counsel to the Registrant, at (212) 479-6495. Very truly yours, Addex Therapeutics Ltd. /s/ Tim Dyer Tim Dyer Chief Executive Officer cc: Josh Kaufman, Cooley LLP Marc Recht, Cooley LLP David C. Boles, Cooley (UK) LLP Frank Gerhard, Homburger AG